OPKO Health (NASDAQ:OPK) Posts Earnings Results, Hits Expectations

Key Points

• OPKO met EPS expectations with a quarterly loss of $0.07 per share, but revenue of $130.83 million fell short of estimates and declined 56.9% year over year.
• OPKO agreed to sell substantially all remaining BioReference operations to Labcorp for about $722 million in cash, plus potential 4Kscore royalties, as it shifts focus toward biotech and global products.
• Revenue from continuing operations increased 16% to $65.4 million, though the company expects substantial sale-related and discontinued-operations costs; it withdrew consolidated full-year guidance and forecast continuing-operations revenue of $268 million–$278 million.

OPKO Health (NASDAQ:OPK - Get Free Report) issued its quarterly earnings results on Wednesday. The biotechnology company reported ($0.07) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.07), FiscalAI reports. The company had revenue of $130.83 million for the quarter, compared to the consensus estimate of $136.62 million. OPKO Health had a negative net margin of 12.40% and a negative return on equity of 5.88%. The firm's quarterly revenue was down 56.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.03 EPS.

Here are the key takeaways from OPKO Health's conference call:

• OPKO agreed to sell substantially all of BioReference’s remaining operations to Labcorp for about $722 million in cash, with potential 4Kscore royalties of up to $150 million over 10 years. The deal, which remains subject to customary closing conditions, would complete OPKO’s exit from diagnostics and refocus it on biotech and global products.
• Continuing-operations revenue rose 16% to $65.4 million year over year, led by OPKO Iberoamerica, RAYALDEE and mazdutide royalties. Global products reported $6 million of operating income, versus a $1.2 million loss a year earlier.
• Pipeline programs advanced, including completion of enrollment in the planned phase I cohorts for MDX-2301, with management describing its blinded safety profile as favorable. OPKO is preparing subcutaneous dosing studies for several ModeX candidates, while its first in vivo CAR-T program is now targeted for first-in-human studies in mid-2027, later than previously planned.
• Innovative biotech’s operating loss widened to $26.8 million from $22.5 million, as increased research and development activity raised costs. OPKO expects about $125 million in BioReference sale-related costs, and forecast a roughly $40 million loss from discontinued operations in Q4.
• OPKO ended the quarter with $403.2 million in cash, cash equivalents and restricted cash, and repurchased 7.2 million shares for $10.6 million. It withdrew consolidated full-year guidance and issued continuing-operations revenue guidance of $268 million–$278 million; management said it would provide more detail on capital allocation as the Labcorp closing approaches.

OPKO Health Stock Performance

Shares of OPK stock traded up $0.05 during trading on Wednesday, reaching $1.77. 4,819,446 shares of the company's stock traded hands, compared to its average volume of 5,615,405. The company has a market capitalization of $1.32 billion, a P/E ratio of -19.67 and a beta of 1.52. The company has a current ratio of 3.35, a quick ratio of 2.93 and a debt-to-equity ratio of 0.28. The firm's 50-day moving average is $1.58 and its 200 day moving average is $1.35. OPKO Health has a 1 year low of $0.98 and a 1 year high of $1.81.

Analyst Upgrades and Downgrades

OPK has been the subject of a number of research analyst reports. HC Wainwright restated a "buy" rating on shares of OPKO Health in a report on Friday, October 16th. Weiss Ratings reiterated a "sell (d-)" rating on shares of OPKO Health in a research note on Thursday, August 13th. Piper Sandler reissued an "overweight" rating and set a $4.00 target price (up from $3.00) on shares of OPKO Health in a research report on Friday, October 16th. Zacks Research upgraded shares of OPKO Health from a "hold" rating to a "strong-buy" rating in a research note on Monday, September 28th. Finally, UBS Group set a $4.00 price target on shares of OPKO Health in a report on Friday, October 16th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, OPKO Health has a consensus rating of "Moderate Buy" and a consensus target price of $3.42.

OPKO Health Company Profile

OPKO Health, Inc is a healthcare company focused on diagnostics and pharmaceuticals. Through its BioReference Laboratories business, the company provides clinical laboratory services, including routine testing, specialty diagnostics, genetic testing and oncology-related laboratory services. OPKO also develops diagnostic products, including the 4Kscore test, a blood test designed to help assess the risk of aggressive prostate cancer.

In pharmaceuticals, OPKO develops treatments for kidney disease, endocrine disorders and other conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.